For primary hyperlipidemia. ANDA 205955, held by Sawai USA. Pitavastatin Calcium.
As of Nov 16, 2026, ANDA 205955 (Pitavastatin Calcium), held by Sawai USA, was first approved by FDA on Feb 3, 2017, with 2 approved supplements and 0 published complete response letters.
Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 3, 2017 | Original application | Approved | None posted |
| Pitavastatin CalciumEQ 1MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 2MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 4MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Nov 4, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 22, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 3, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters